Results 51 to 60 of about 18,764 (290)
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
Pharmaceuticals, 2023 Despite decades of research and numerous clinical trials, the prognosis of patients diagnosed with glioblastoma (GBM) remains dire with median observed survival at 8 months.
M. Webb, U. Sener, R. Vile
semanticscholar +1 more source
Oncolytic Viruses and the Immune System: The Dynamic Duo
Molecular Therapy: Methods & Clinical Development, 2020 Oncolytic viruses (OVs) constitute a new and promising immunotherapeutic approach toward cancer treatment. This therapy takes advantage of the natural propensity of most tumor cells to be infected by specific OVs.
Ana Lemos de Matos +2 more
doaj +1 more source
Lung cancer and oncolytic virotherapy——enemy's enemy
Translational Oncology, 2023 Lung cancer is one of the malignant tumors that seriously threaten human health worldwide, while the covid-19 virus has become people's nightmare after the coronavirus pandemic. There are too many similarities between cancer cells and viruses, one of the
Zhang Li +3 more
doaj +1 more source
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter [PDF]
, 2016 Ad vectors are promising delivery vehicles for cancer therapeutic interventions. However, their application is limited by promiscuous tissue tropism and hepatotoxicity. This limitation can be avoided by altering the native tropism of Ads so that they can
Bhatia, Shilpa +4 more
core +3 more sources
Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy
Frontiers in Immunology, 2023 Every type of cancer tissue is theoretically more vulnerable to viral infection. This natural proclivity has been harnessed as a new anti-cancer therapy by employing oncolytic viruses (OVs) to selectively infect and destroy cancer cells while providing ...
Matin Ghasemi +5 more
semanticscholar +1 more source
Exploiting tumor epigenetics to improve oncolytic virotherapy [PDF]
, 2013 Oncolytic viruses (OVs) comprise a versatile and multi-mechanistic therapeutic platform in the growing arsenal of anticancer biologics. These replicating therapeutics find favorable conditions in the tumor niche, characterized among others by increased ...
Hesham Abdelbary +4 more
core +1 more source
Personalizing Oncolytic Virotherapy?
Molecular Therapy, 2007 raditionally, cancer therapies have been based on the empiric discovery of drugs and/or biological agents that act selectively against tumor cells. Recently, however, a generation of rationally discov-ered drugs and agents has been developed that shows encouraging benefi t in treating cancers.
Kaur, Balveen, Chiocca, E Antonio
openaire +2 more sources
Frontiers in Immunology, 2020 Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
Andrew G. Diamos +13 more
doaj +1 more source
Current strategies in engaging oncolytic viruses with antitumor immunity
Molecular Therapy: Oncolytics, 2021 Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni +2 more
doaj +1 more source
Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction. [PDF]
, 2017 LuIII, a protoparvovirus pathogenic to rodents, replicates in human mitotic cells, making it applicable for use to kill cancer cells. This virus group includes H-1 parvovirus (H-1PV) and minute virus of mice (MVM).
Agbandje-McKenna, Mavis +13 more
core +3 more sources